To evaluate hydroxyurea and imatinib treatment for chronic myeloid leukemia
| ISRCTN | ISRCTN54990932 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN54990932 |
| Protocol serial number | 2004-08-CHN |
| Sponsor | Heilongjiang Institute for Hematology and Oncology Research |
| Funders | National Natural Science Foundation of China, China 863 Projects Foundation, No. 2012AA020903 (China) |
- Submission date
- 11/01/2016
- Registration date
- 14/01/2016
- Last edited
- 01/11/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Chronic myeloid leukemia (CML) is a cancer in which the bone marrow makes too many white blood cells. These cells are called granulocytes or leukemia cells; they are abnormal and do not become healthy white blood cells. The leukemia cells can build up in the blood and bone marrow so there is less room for healthy white blood cells, red blood cells, and platelets. When this happens, infection, anemia, or easy bleeding may occur. Most people with CML have a gene mutation (BCR-ABL gene) called the Philadelphia chromosome. The goal of treatment is to eliminate the blood cells that contain the abnormal BCR-ABL gene. For most patients, it's not possible to get rid of all leukemia cells, but treatment can help achieve a long-term remission of the disease. Current treatment choices include: targeted drugs like Imatinib (Gleevec), blood stem cell transplant, chemotherapy, and biological therapy. Each treatment option has its own advantages and disadvantages. The prognosis for patients with advanced CML is usually poor, as the treatments available to these patients often do not work. Hydroxyurea is a type of chemotherapy drug called an antimetabolite. Antimetaboloites work by stopping cells making and repairing DNA; cancer cells need to do both these things in order grow and multiply. However, hydroxyurea may also cause the number of bone marrow blood cells to fall to a very low number. This increases the risk of serious bleeding and infection. It may also cause other cancers, including skin cancer. In light of how well hydroxyurea works and its side effects, it may be possible for patients to not take it for as long and still get the same amount of benefit from the treatment. Imatinib is a type of biological therapy called a tyrosine kinase inhibitor. Tyrosine kinases are proteins that act as chemical messengers that cells use to signal to each other to grow. Imatinib works by blocking certain types of tyrosine kinases. This stops the cancer cells from growing. The dose (amount) of Imatinib given to CML patients is usually high and given for the rest of the patients life. Side effects can include swelling or puffiness of the skin, nausea, muscle cramps, rash, fatigue, diarrhea, and skin rashes. In addition to this, patients may not respond or become resistant to the drug. This study looks at treating CML patients with hydroxyurea for a very short period of time (usually 3 to 7 days) to stop the growth of leukemia cells and then a much reduced dose of Imatinib. It is hoped that the combined function of these two drugs will significantly reduce the dose that patients need to take, improve the patients quality of life, improve both liver and kidney function, reduce drug side effects and decrease the risk of drug resistance.
Who can participate?
Patients diagnosed with CML.
What does the study involve?
All participants are treated with hydroxyurea combined with imatinib. Samples of blood and bone marrow are taken and tested every 6 months to test for progression of the disease. All participants are given the treatment for the rest of their lives and are followed up every 6 months for at least 5 years or until their death.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
First Affiliated Hospital of Harbin Medical University (China)
When is the study starting and how long is it expected to run for?
May 2003 to December 2024
Who is funding the study?
National Natural Science Foundation of China
Who is the main contact?
Professor Jin Zhou
zhoujin1111@126.com
Contact information
Scientific
Department of Hematology
First Affiliated Hospital
Harbin Medical University
Harbin
150001
China
| Phone | +86 (0) 451 53641824 |
|---|---|
| zhoujin1111@126.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Interventional |
| Secondary study design | Non randomised study |
| Study type | Participant information sheet |
| Scientific title | Prospective study on an effective treatment for chronic myeloid leukemia with hydroxyurea and imatinib |
| Study objectives | Short period use of hydroxyurea combined with low-dose imatinib function cooperatively will improve the clinical outcome for chronic myeloid leukemia (CML) patients during treatment at accelerated phase and blastic phase. |
| Ethics approval(s) | Harbin Medical University Ethics Committee, 3/20/2002, ref: HM011502. |
| Health condition(s) or problem(s) studied | Chronic myeloid leukemia (CML) |
| Intervention | Chronic myeloid leukemia (CML) patients who give written consent are enrolled. First stage is to control leukocytosis, which includes daily oral hydroxyurea 1-3 g for 3-7 days. A total of three treatment cycles are repeated with 2-week intervals until leukocytosis is well controlled. For CML cell elimination therapy, oral imatinib of 200-600 mg/day is maintained for life. Blood and bone marrow cell study, biopsy, and cytogenetics are tested once every 6 months. The total duration of treatment is life time, and follow-up for all treatment arms is from diagnosis, then once every 6 months, until death or 5 years and beyond. |
| Intervention type | Mixed |
| Primary outcome measure(s) |
1. Overall survival (OS): It is calculated from the start of the treatment until the last follow up or death |
| Key secondary outcome measure(s) |
1. Complete hematologic remission (CHR) - Normal complete blood count and normal physical examination |
| Completion date | 31/12/2024 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | All |
| Sex | All |
| Target sample size at registration | 2000 |
| Key inclusion criteria | 1. Any age CML patients at different disease stages, who are responsive or non-responsive to conventional treatments are all included in this trial 2. Patients agreed to receive the treatment |
| Key exclusion criteria | 1. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc.) 2. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc.) 3. Illegal drug use or chronic alcoholism 4. Physical limitations, mental or intellectual disabilities 5. Any condition that may affect the development of this trial |
| Date of first enrolment | 01/05/2003 |
| Date of final enrolment | 30/01/2024 |
Locations
Countries of recruitment
- China
Study participating centre
First Affiliated Hospital
Harbin Medical University
Harbin
150001
China
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
01/11/2017: Internal review.
